Centrus: A Historic Centrifuge, $2.2 Billion of Cash — and a Stock Down 54%
The quarter that proved US enrichment manufacturing is real also showed a shrinking top line, a gross loss, and a market that stopped paying for the story.
LEU · Earnings Call · 2026-11-05
The milestone the tape refused to celebrate
On paper this was Centrus's best operational quarter in years. The company shipped its first centrifuge out of Oak Ridge ahead of its year-end target, doubled its contingent enrichment commitments, and began enriching commercial HALEU on its existing cascade. Management wanted the moment savored:
We now proved that US centrifuge manufacturing is a reality. It is a historic milestone for Centrus and The United States.
And yet the equity is in a violent drawdown. The stock is down 46.5% over 90 days and roughly 54% from its August 27 peak of $194.78, part of a broader unwind in the nuclear-power-for-AI complex — the AI data center infrastructure basket on the global tape is down roughly 31% over three months. So the selloff is partly sector beta, not company alpha.
But there is a stranger fact buried in the print. Management reported ending the quarter with roughly $2.2 billion of unrestricted cash — against a market capitalization of about $1.76 billion. A company whose enterprise value is arguably negative on a headline basis just told you it grew its enrichment backlog to $7 billion and is the only Western commercial HALEU enricher. Either the cash is real and the market is mispricing an execution-risk story, or the cash is being pre-spent on a build that the market expects to consume it. That tension is the whole quarter.
What genuinely changed
Three things are not boilerplate. First, backlog moved from $3 billion to $5.4 billion in contingent LEU and HALEU sales commitments, of which $5.1 billion sits under definitive agreements, extending out to 2040. Second, Centrus bought its way down the supply chain: the acquisition of Westermann for ~$116 million (majority cash) turned a critical casing supplier into a captive subsidiary and an immediately accretive revenue stream. Amir Vexler framed it as a one-move derisk: “In 1 strategic move, we have simultaneously derisked our build out by securing a key supplier and a best-in-class manufacturer of centrifuge casing and other critical components.” — Amir Vexler, President and Chief Executive Officer · 2026-11-05 Third, the customer mix is broadening from utilities to advanced-reactor names — the micro reactors and SMR developers that are now putting fuel at the front of their plans.
The tell is in the company's own momentum history: Westermann registered as the single biggest keyword gainer of the quarter, and derisk, optionality and disparity all spiked. This is a management team narrating a shift from "we have a contract book" to "we are building an industrial machine" — heavy on investment grade utilities as the anchor of the base-load LEU business, with HALEU as the call option on top.
The bill for the build
Here is where the tape's skepticism earns its keep. “Total revenue for the third quarter was $55.5 million a decrease of $19.4 million, or 26%, versus the same period last year.” — Todd Tinelli, Senior Vice President, Chief Financial Officer · 2026-11-05 Worse, the quarter flipped to a gross loss of $10.6 million, and normalized loss per share was $0.49 — versus normalized income of $0.19 a year earlier. Todd Tinelli leaned on timing and the trailing-twelve-month frame: “there is a lot of timing around when we receive product and mismatch of when we deliver product.” — Todd Tinelli, Senior Vice President, Chief Financial Officer · 2026-11-05 He is right that TTM revenue of $454.5 million and TTM gross profit of $105.8 million tell a steadier story than any single quarter. But a 28.3% gross margin in the June quarter that just printed negative the following quarter is exactly the kind of volatility that rattles a name priced for a decade of growth.
The capital intensity is the real story. capital expenditure of $72 million in Q2, up roughly 1,889% year over year is only the beginning — Q3 total capital spend hit $134 million, and full-year guidance is $350–500 million. That is a company spending roughly a fifth to a quarter of its market cap on capex annually. The growth costs line, and the $46.4 million non-cash warrant gain that management had to strip out to present "normalized" numbers, add to the GAAP opacity. Fund the build with a $500 million equity-plus-warrant raise on top of the swollen balance sheet — with warrants potentially worth ~$2 billion more if exercised — and investors are being asked to underwrite dilution against a cash pile that the equity market is currently valuing at less than par.
The de-rating shows it. price-to-revenue de-rated from 12.4x to 7.1x, even as management reported record commitments. The market has decided the backlog is long-dated and the cash will be consumed before it converts.
What management stopped talking about
The most revealing signal is what vanished from the script. In August, SWU pricing was the CEO's "favorite question" — “SWU prices have been escalating and have -- are still escalating due to the simple fact that you have demand that is outstripping supply.” — Amir Vexler, President and Chief Executive Officer · 2026-08-06 This quarter, SWU price fell off as a top theme and pricing got almost no airtime; the narrative moved to manufacturing cadence and supply-chain control. Likewise lead time, a near-obsession in early 2026 ("“lead time is extremely important as an opportunity as well as cost out” — Amir Vexler, President and Chief Executive Officer · 2026-08-06"), slipped as a talking point. That is not a bearish tell by itself — the build is now the priority — but it means the pricing tailwind that drove the 2025 melt-up is no longer the story management wants you to focus on.
Instead, much of the forward detail was deferred to the December 7 Investor Day at Piketon: ramp cadence, Westermann's segment margins, 2027 capital plans, and the Palantir cost-savings trajectory all got the same answer. On Palantir's $300 million of identified savings, Vexler was candid that “most of the opportunities and most of the potential savings and value we are going to derive is still ahead of us.” — Amir Vexler, President and Chief Executive Officer · 2026-11-05
The bet in one line
Centrus is no longer a brokerage business with a HALEU option; it is a capital-hungry industrial build with a ~$7 billion backlog, the only Western commercial HALEU cascade spinning, and a balance sheet that, on management's own numbers, is worth more than the equity. effective net cash of $724 million at Q2 was already large; $2.2 billion is extraordinary relative to a $1.76 billion cap. Whether that is a mispricing or a warning depends entirely on execution — on cycle times, on converting contingent commitments into cash flow, and on not letting the build eat the fortress. This call proved the first centrifuge is real. It did not yet prove the margin is. That is what December 7 is for.